Logo image of ALMDT.PA

MEDIAN TECHNOLOGIES (ALMDT.PA) Stock Fundamental Analysis

EPA:ALMDT - Euronext Paris - Matif - FR0011049824 - Common Stock - Currency: EUR

1.886  -0.05 (-2.68%)

Fundamental Rating

2

Overall ALMDT gets a fundamental rating of 2 out of 10. We evaluated ALMDT against 10 industry peers in the Health Care Technology industry. ALMDT may be in some trouble as it scores bad on both profitability and health. ALMDT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year ALMDT has reported negative net income.
In the past year ALMDT has reported a negative cash flow from operations.
In the past 5 years ALMDT always reported negative net income.
In the past 5 years ALMDT always reported negative operating cash flow.
ALMDT.PA Yearly Net Income VS EBIT VS OCF VS FCFALMDT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -103.56%, ALMDT is not doing good in the industry: 90.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -103.56%
ROE N/A
ROIC N/A
ROA(3y)-75.23%
ROA(5y)-63.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALMDT.PA Yearly ROA, ROE, ROICALMDT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600

1.3 Margins

Looking at the Gross Margin, with a value of 103.86%, ALMDT belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
ALMDT's Gross Margin has been stable in the last couple of years.
ALMDT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 103.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.46%
GM growth 5Y0.99%
ALMDT.PA Yearly Profit, Operating, Gross MarginsALMDT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

0

2. Health

2.1 Basic Checks

ALMDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALMDT has more shares outstanding
ALMDT has more shares outstanding than it did 5 years ago.
ALMDT has a worse debt/assets ratio than last year.
ALMDT.PA Yearly Shares OutstandingALMDT.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALMDT.PA Yearly Total Debt VS Total AssetsALMDT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ALMDT has an Altman-Z score of -10.48. This is a bad value and indicates that ALMDT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.48, ALMDT is doing worse than 80.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.48
ROIC/WACCN/A
WACC6.28%
ALMDT.PA Yearly LT Debt VS Equity VS FCFALMDT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

ALMDT has a Current Ratio of 0.47. This is a bad value and indicates that ALMDT is not financially healthy enough and could expect problems in meeting its short term obligations.
ALMDT has a Current ratio of 0.47. This is amonst the worse of the industry: ALMDT underperforms 90.00% of its industry peers.
ALMDT has a Quick Ratio of 0.47. This is a bad value and indicates that ALMDT is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.46, ALMDT is doing worse than 90.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.46
ALMDT.PA Yearly Current Assets VS Current LiabilitesALMDT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

6

3. Growth

3.1 Past

The earnings per share for ALMDT have decreased by -8.88% in the last year.
The Revenue has been growing slightly by 3.25% in the past year.
The Revenue has been growing by 20.72% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-8.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.92%
Revenue 1Y (TTM)3.25%
Revenue growth 3Y3.75%
Revenue growth 5Y20.72%
Sales Q2Q%10.21%

3.2 Future

Based on estimates for the next years, ALMDT will show a very strong growth in Earnings Per Share. The EPS will grow by 28.50% on average per year.
Based on estimates for the next years, ALMDT will show a very strong growth in Revenue. The Revenue will grow by 27.00% on average per year.
EPS Next Y23.12%
EPS Next 2Y28.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year17.88%
Revenue Next 2Y24.31%
Revenue Next 3Y27%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALMDT.PA Yearly Revenue VS EstimatesALMDT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
ALMDT.PA Yearly EPS VS EstimatesALMDT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -0.5 -1

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALMDT. In the last year negative earnings were reported.
Also next year ALMDT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALMDT.PA Price Earnings VS Forward Price EarningsALMDT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALMDT.PA Per share dataALMDT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

ALMDT's earnings are expected to grow with 28.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.5%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ALMDT!.
Industry RankSector Rank
Dividend Yield N/A

MEDIAN TECHNOLOGIES

EPA:ALMDT (8/6/2025, 7:00:00 PM)

1.886

-0.05 (-2.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)04-29 2025-04-29/amc
Earnings (Next)10-22 2025-10-22
Inst Owners18.08%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap37.59M
Analysts85.45
Price Target17.07 (805.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.01%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-3.44%
Revenue NY rev (3m)-3.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.64
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.37
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS1.15
BVpS-1.7
TBVpS-1.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -103.56%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 103.86%
FCFM N/A
ROA(3y)-75.23%
ROA(5y)-63.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.46%
GM growth 5Y0.99%
F-Score3
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.59%
Cap/Sales 4.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.47
Quick Ratio 0.46
Altman-Z -10.48
F-Score3
WACC6.28%
ROIC/WACCN/A
Cap/Depr(3y)102.16%
Cap/Depr(5y)84.24%
Cap/Sales(3y)5.46%
Cap/Sales(5y)4.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.92%
EPS Next Y23.12%
EPS Next 2Y28.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.25%
Revenue growth 3Y3.75%
Revenue growth 5Y20.72%
Sales Q2Q%10.21%
Revenue Next Year17.88%
Revenue Next 2Y24.31%
Revenue Next 3Y27%
Revenue Next 5YN/A
EBIT growth 1Y2.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.31%
OCF growth 3YN/A
OCF growth 5YN/A